Indian COVID-19 vaccine maker asks US to ease embargo on raw material exports

Published: Updated:
Read Mode
100% Font Size
3 min read

The chief executive of Serum Institute of India, the world’s largest maker of vaccines and a critical supplier of the UN-backed COVAX facility, asked President Joe Biden on Twitter to lift the US embargo on exporting raw materials needed to make the jabs.

Vaccine makers and experts in India have been concerned that the use of the Defense Production Act by the US to boost their own vaccine production was resulting in exports of critical raw materials being stopped. This was hobbling vaccine production in other parts of the world.

For all the latest headlines follow our Google News channel online or via the app.

Stéphane Bancel, chief executive officer for Moderna, said Tuesday in an online event that export embargoes were also preventing American vaccine makers from exporting shots globally and resulting in shortages.

“If we are to truly unite in beating this virus, on behalf of the vaccine industry outside the US, I humbly request you to lift the embargo of raw material exports out of the US so that vaccine production can ramp up,” wrote Adar Poonawalla, CEO of Serum Institute of India.

He had earlier told The Associated Press that pivoting away from suppliers in the US could result in a delay of up to six months for the production of the COVID-19 vaccine developed by Novavax. Serum Institute and Novavax have inked a deal to supply 1.1 billion doses of the vaccine to COVAX to equitably distribute it across the globe.

Serum Institute of India paused exports to COVAX after a devastating surge of infections in India resulted in increased domestic demand.

Over 200,000 new infections were detected in the past 24 hours and major cities, like Mumbai and New Delhi, are under virus restrictions. Hospitals are overwhelmed and authorities are scrambling to try and vaccinate enough people to slow down the spread. But in doing so, India relies heavily on AstraZeneca shots made by Serum Institute of India.

Poonawalla had said the unavailability of the raw materials, such as the specific medium needed to grow microorganisms, would prevent Serum Institute from scaling up the production of the vaccine developed by Novavax.

The company had been planning to make up to 40 million shots of the vaccine monthly.

Ramping up the production of this shot could also help India. Novavax has applied for authorization of the vaccine to regulators in Europe, the US and the World Health Organization.

If approved, India would be able to use the shot under new regulations that make it easier to greenlight vaccines that have received the nod by the UK, the US, Europe, Japan or WHO.

Read more:

Young adults infected with COVID-19 risk catching disease again, study says

Migrant workers fill Mumbai trains as COVID-19 situation dries up jobs

COVID-19 infection rate approaching highest of pandemic so far: WHO chief

Top Content Trending